E-DRUG: Nimesulide safety?
--------------------------
Hello e-druggers,
I Sivasankaran Ponnusankar, practising as a clinical pharmacist in a 420
bed secondary care teaching government hospital in Ooty.
It is a hill station.
The Tamilnadu state has its own essential drug list for all the government
hospital use in the state. This is the only state which has an essential
list in India. Recently Delhi territory also introduced an essential list.
It has more than 370 drugs.
The local practitioners (GP's) of my town want to know about the adverse
profile of the drug NIMESULIDE (the pharmaceutical company promoting this
drug as selective cox2 inhibitor drug) and I personally want to know about
approval of different agencies in US, UK and other europian countries. I
feel it is available in India only (I may be wrong). The practitioners in
India started prescribing this drug very much. We are worry about the
adverse profile about this on chronic use. And of course this has been
prescribed to a simple pain in paediatrics too. We tried to get the
information from IDIS, but unfortunately I couldn't able to collect more
information.
Can any one of you guide me or send the information about this drug. This
help of e-druggers will be appreciated.
Thanking you.
Faithfully yours,
Sivasankaran Ponnusankar.
ponnusankarsivas@hotmail.com
My address:
Sivasankaran Ponnusankar,
Clinical Pharmacist,
Dept. of Pharmacy Practice,
JSS College of Pharmacy,
Ooty - 643 001.
The Nilgiris, India.
e-mail: ponnusankarsivas@hotmail.com
[I am always surprised how quickly new drugs get introduced in developing
countries. New drugs often have unknown rare side-effects, and it is
unlikely that these get reported. New drugs are also much more expensive
than well-known old drugs. Marketing and not evidence based medicine
appears to be the main reason for the fast 'acceptance' of these New
Chemical Entities in developing countries. New drugs rarely become
immediately essential. A conservative approach seems to be advisable: let
the rich, developed countries test those new drugs: they can afford them,
and they also are better in finding out their safety profile.
There was already a big discussion on nimesulfide in E-drug. Please check
our E-drug archives at http://www.healthnet.org/programs/edrug.html
and search the archives for nimesulfide.
If you don't have access to Internet, send me a personal email (to
WilbertBannenberg@compuserve.com and I will dog out those emails for you).
WB]
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.